comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 21:47:42 - browse：7921

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Beware the threat of staffing cuts at the CDC

WSS

Hilary expected to bring catastrophic, life

New definition of a human embryo proposed amid rapid advances

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Ukraine taking heavy casualties 10 weeks into its counteroffensive

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

FDA investigates CAR

Wikipedia

comprehensive

focus

Duchenne breakthrough therapy leaves behind pioneering families

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Apple is now the first public company to be valued at $3 trillion

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Heart attack and stroke risk calculators need revising

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Psychedelics group wrestles with new pharma identity

The EPA's new lead rule: How one expert crunched the numbers

Medical leaders decry Supreme Court decision on affirmative action

Trump cancels press conference intended to dispute Georgia election interference charges

focus

Ukraine taking heavy casualties 10 weeks into its counteroffensive

How to pay for weight loss drugs and save Medicare

Will the market for weight loss drugs really reach $100 billion?

New details revealed about Purdue's marketing of OxyContin

Takeda, Janssen join wearable maker to measure scratching

Organ aging and disease risk measured by new blood test

focus

explore

Wikipedia

explore